• Opinion: The Morris ALS Principles: A model for empowering all disease communities

    19 days ago - By STAT

    The FDA's decision to delay its highly anticipated review of AMX0035 , a new drug for treating amyotrophic lateral sclerosis, until September highlights an ongoing rift between the needs of people directly affected by ALS and those responsible for bringing forth treatments and cures.
    ALS is a devastating neurodegenerative disease that typically kills within three years of diagnosis. People living with it do not have time to waste. Many of them also have strong opinions and keen insights into treating the disease. They and their family members must be engaged as partners - not just as...
    Read more ...